ポスト
$DVAX said the U.S. FDA rejected the company's supplemental Biologics License Application for expanded use of its four-dose hepatitis B vaccine for adults on hemodialysis.
メニューを開く$DVAX said the U.S. FDA rejected the company's supplemental Biologics License Application for expanded use of its four-dose hepatitis B vaccine for adults on hemodialysis.
メニューを開く
